Aplastic Anemia

Zahra Pakbaz MD is a board certified hematologist and associate clinical professor. in collaboration with her other team members, Dr Pakbaz provides comprehensive care for hematological disorders including bone marrow failures aplastic anemia, and MDS, Paroxysmal Nocturnal Hemoglobinuria (PNH) and other rare anemias as well as Myeloproliferative Neoplasm (polycythemia vera, essential thrombocytosis, myelofibrosis) and LGL She is passionate about delivering patient-centered care to people with blood disorders, and she works collaboratively with primary care physicians and other specialists. She

Dr. Paibel Aguayo-Hiraldo, MD is a pediatric hematologist oncologist in Los Angeles, CA and has over 15 years of experience in the medical field. She graduated from Saint Lukes Medical Center / School of Radiation Therapy-radiation Oncology in 2009. She is affiliated with Children's Hospital Los Angeles.

In her approach to patient care, cardio-oncologist June-Wha Rhee, M.D., puts listening first. She aims to understand patients' desires, priorities, concerns and experiences. Fascinated with the heart, she has dedicated her career to finding new ways to prevent or minimize cardiovascular complications from cancer treatment. Dr. Rhee earned a bachelor’s degree from Massachusetts Institute of Technology and a medical degree from Harvard. During her postgraduate training at Stanford, she was a resident in internal medicine, a fellow in cardiovascular medicine — including a stint as chief fellow —

Dr. Ball received his medical degree at Georgetown University in Washington, DC, then continued his training at Yale-New Haven Hospital and Memorial Sloan Kettering Cancer Center in New York City. At Yale, he co-directed the school’s Refugee Health Clinic. He’s earned numerous honors and awards, including being selected as chief fellow at Memorial Sloan Kettering and Yale’s coveted Global Health Scholar program enabling him to study in South Africa. Dr. Ball has a keen interest in researching the molecular mechanisms mediating resistance to current leukemia treatments. One of his proposals for